Education
About Us
Working with TipRanks
Follow Us
Acarix AB (SE:ACARIX)
:ACARIX
Top Page
Acarix AB
(Frankfurt:ACARIX)
46Neutral
Acarix AB (ACARIX) vs. S&P 500 (SPY)
Market Cap
kr223.39M
Dividend YieldN/A
Average Volume (3M)828.97K
Price to Earnings (P/E)―
Beta (1Y)-0.88
Revenue Growth-0.61%
EPS Growth54.19%
CountrySE
Employees8
SectorHealthcare
Sector Strength60
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.07
Shares Outstanding1,063,743,800
10 Day Avg. Volume592,055
30 Day Avg. Volume828,973
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Acarix AB Business Overview & Revenue Model
Company DescriptionAcarix AB (ACARIX) is a medical technology company specializing in diagnostic solutions for coronary artery disease. The company is focused on non-invasive, innovative products that aid in the early detection and management of heart disease. Acarix is particularly known for its CADScor System, which provides a quick and reliable way to rule out significant coronary artery disease in patients with chest pain symptoms.
How the Company Makes MoneyAcarix AB generates revenue primarily through the sale of its CADScor System devices and related services. The company sells these diagnostic devices to healthcare providers, clinics, and hospitals, which use them to assess patients for coronary artery disease. Acarix may also generate income through service agreements or maintenance contracts linked to the ongoing use of its technology. Partnerships with healthcare institutions and collaborations with research entities can also play a role in expanding its market reach and enhancing its revenue streams.
Acarix AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 6.20M | 6.24M | 5.82M | 3.76M | 2.17M | Gross Profit |
| 5.59M | 5.30M | 4.62M | 2.82M | 1.59M | EBIT |
| -66.37M | -77.55M | -76.47M | -51.70M | -41.43M | EBITDA |
| -62.63M | -77.12M | -76.12M | -50.52M | -40.29M | Net Income Common Stockholders |
| -66.19M | -77.84M | -77.50M | -51.80M | -41.55M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 53.99M | 35.15M | 6.62M | 15.81M | 64.06M | Total Assets |
| 80.76M | 62.88M | 69.48M | 118.60M | 89.95M | Total Debt |
| 0.00 | 0.00 | 251.00K | 523.00K | 1.37M | Net Debt |
| -53.99M | -35.15M | -6.37M | -15.29M | -62.70M | Total Liabilities |
| 5.06M | 11.00M | 17.66M | 18.06M | 7.81M | Stockholders Equity |
| 75.70M | 51.88M | 51.83M | 100.54M | 82.14M |
| Cash Flow | Free Cash Flow | |||
| -64.25M | -81.37M | -75.02M | -48.05M | -36.69M | Operating Cash Flow |
| -63.33M | -81.37M | -74.87M | -48.01M | -36.69M | Investing Cash Flow |
| -920.00K | 0.00 | -151.00K | -43.00K | 0.00 | Financing Cash Flow |
| 86.98M | 106.23M | 69.03M | -164.00K | 47.35M |
Acarix AB Technical Analysis
Negative
0.21
Price Trends
0.23
Negative
0.24
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
39.81
Neutral
20.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACARIX, the sentiment is Negative. The current price of 0.21 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.23, and below the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.81 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACARIX.
Acarix AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
50 Neutral | kr444.95M | ― | -33.80% | ― | 72.05% | 33.68% | |
46 Neutral | kr223.39M | ― | -102.63% | ― | -0.61% | 54.19% | |
43 Neutral | €285.45M | ― | -12.79% | ― | -6.43% | -323.52% | |
43 Neutral | kr131.94M | ― | -151.03% | ― | 27.78% | 43.32% | |
37 Underperform | €157.90M | ― | -159.24% | ― | -22.50% | 76.74% | |
28 Underperform | €79.55M | ― | -19.16% | ― | ― | -13.59% |
* Healthcare Sector Average
Performance Comparison
SE:ACARIX
Acarix AB
0.21
-0.08
-27.08%
SE:INTEG.B
Integrum AB Class B
14.86
-37.34
-71.53%
SE:QLINEA
Q-linea AB
0.04
-0.28
-88.61%
SE:SCIB
SciBase Holding AB
0.39
0.08
25.82%
SE:SPEC
SpectraCure AB
0.77
-2.27
-74.67%
SE:BRAIN
BrainCool AB
1.66
-0.14
-7.86%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.